Related Experiment Videos
Endothelin and pulmonary arterial hypertension
Yolanda Braun-Moscovici1, A Menahem Nahir, Alexandra Balbir-Gurman
1B. Shine Department of Rheumatology, Rambam Medical Center, Haifa, Israel.
Seminars in Arthritis and Rheumatism
|August 12, 2004
Summary
Endothelin (ET) plays a critical role in pulmonary arterial hypertension (PHT). ET receptor antagonists represent a promising therapeutic option for PHT, shifting treatment from vasodilators to antiproliferative agents.
Area of Science:
- Cardiovascular Medicine
- Pulmonology
- Pharmacology
Background:
- Pulmonary arterial hypertension (PHT) is a severe condition linked to various heart and lung diseases.
- The endothelin (ET) system is implicated in the pathogenesis of PHT, contributing to vascular remodeling.
- PHT progression involves vasoconstriction and pulmonary vascular obstruction.
Purpose of the Study:
- To review current knowledge on the role of endothelin (ET) in pulmonary arterial hypertension (PHT).
- To discuss relevant drug regimens for treating PHT, focusing on ET-targeted therapies.
Main Methods:
- A comprehensive literature search was conducted using MEDLINE (PubMed).
- Key search terms included Pulmonary Arterial Hypertension (PHT) and Endothelin (ET).
Main Results:
- ET system activation is crucial in PHT development, driving vascular proliferation.
- Prostacyclin infusion improves PHT symptoms and survival but has side effects.
- Bosentan, an ET receptor antagonist, shows promise for PHT treatment due to its vasodilator and antiproliferative effects.
Conclusions:
- Understanding PHT pathogenesis has shifted focus to antiproliferative and vascular remodeling drugs.
- ET blockade offers a potential therapeutic strategy for PHT.
- Newer treatments like ET receptor antagonists are emerging as valuable options for PHT management.